Тематические порталы ИД "Русский врач": Кардиология, Педиатрия
 
     



Мероприятия

 

N-ацетилцистеин в лечении инфекций, связанных с образованием биопленок
Автор: Е. Ушкалова   

 

magazine-vrach-2013-11-010

N-ацетилцистеин в лечении инфекций, связанных с образованием биопленок

Обсуждается значение биопленок в развитии хронических и рецидивирующих инфекций и терапевтические стратегии, направленные на их эрадикацию. Приводятся результаты исследований N-ацетилцистеина и механизм его действия на биопленки.
N-acetyl cysteine in the treatment of biofilm formation-associated infections
The paper discusses the significance of biofilms in the development of chronic and recurrent infections and the therapeutic strategies for their eradication. It gives the results of investigations of N-acetyl cysteine and the mechanism of its action on the biofilms.
Литература:
1. Głowacki R., Strek P., Zagórska-Swiezy K. et al. Biofilm from patients with chronic rhinosinusitis. Morphological SEM studies // Otolaryngol. Pol. – 2008; 62 (3): 305–10.
2. Sanchez C. Jr., Mende K., Beckius M. et al. Biofilm formation by clinical isolates and the implications in chronic infections // BMC Infect Dis. – 2013; 13: 47.
3. Tikhomirova A., Kidd S. Haemophilusinfluenzae and Streptococcus pneumoniae: living together in a biofilm // Pathog. Dis. – 2013 Aug. 3 (Epub. ahead of print).
4. Dalton T., Dowd S., Wolcott R. et al. An in vivo polymicrobial biofilm wound infection model to study interspecies interactions // PLoS One. – 2011; 6 (11): 27317.
5. Sun Y., Dowd S., Smith E. et al. In vitro multispecies Lubbock chronic wound biofilm model // Wound Repair Regen. – 2008; 16 (6): 805–13.
6. Peters B., Jabra-Rizk M., O'May G. et al. Polymicrobial interactions: impact on pathogenesis and human disease // Clin. Microbiol. Rev. – 2012; 25 (1): 193–213.
7. Brogden K., Guthmiller J., Taylor C. Human polymicrobial infections // Lancet. – 2005; 365: 253–5.
8. Pintucci J., Corno S., Garotta M. Biofilms and infections of the upper respiratory tract // Eur. Rev. Med. Pharmacol. Sci. – 2010; 14 (8): 683–90.
9. Vlastarakos P., Nikolopoulos T., Maragoudakis P. et al. Biofilms in ear, nose, and throat infections: how important are they? // Laryngoscope. – 2007; 117 (4): 668–73.
10. Macassey E., Dawes P. Biofilms and their role in otorhinolaryngological disease // J. Laryngol. Otol. – 2008; 122 (12): 1273–8.
11. Liu Y., Post J. Biofilms in pediatric respiratory and related infections // Curr. Allergy Asthma Rep. – 2009; 9 (6): 449–55.
12. Kobayashi H. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections // Treat. Respir. Med. – 2005; 4 (4): 241–53.
13. Mietto C., Pinciroli R., Patel N. et al. Ventilator associated pneumonia: evolving definitions and preventive strategies // Respir. Care. – 2013; 58 (6): 990–1007.
14. Bjarnsholt T. The role of bacterial biofilms in chronic infections // APMIS Suppl. – 2013; 136: 1–51.
15. Aslam S., Darouiche R. Role of antibiofilm-antimicrobial agents in controlling device-related infections // Int. J. Artif. Organs. – 2011; 34 (9): 752–8.
16. Голуб А.В. Бактериальные биопленки – новая цель терапии? // Клин. микробиол. антимикроб. химиотер. – 2012; 14 (1): 23–9.
17. Marks L., Davidson B., Knight P. et al. Interkingdom signaling induces Streptococcus pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease // MBio. – 2013; 4 (4): 438–43.
18. Пронина Е.А., Шуб Г.М., Швиденко И.Г. Формирование бактериальных биопленок под воздействием электромагнитного излучения // Фундаментальные исследования. – 2010; 10: 40–6.
19. Lewis K. Multidrug tolerance of biofilms and persister cells // Curr. Top Microbiol. Immunol. – 2008; 322: 107–31.
20. Høiby N., Bjarnsholt T., Givskov M. et al. Antibiotic resistance of bacterial biofilms // Int. J. Antimicrob. Agents. – 2010; 35: 322–32.
21. Johansen H., Moskowitz S., Ciofu O. et al. Spread of colistin-resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients // J. Cyst. Fibros. – 2008; 7: 391–7.
22. Aparna M., Yadav S. Biofilms: microbes and disease // Braz. J. Infect. Dis. – 2008; 12 (6): 526–30.
23. Høiby N., Ciofu O., Johansen H. et al. The clinical impact of bacterial biofilms // Int. J. Oral. Sci. – 2011; 3 (2): 55–65.
24. Solares C., Barta P., Hall G. et al. Treatment of chronic rhinosinusitis exacerbations due to methicillinresistant Staphylococcus aureus with mupirocinirrigation // Am. J. Otolaryngol. – 2006; 27: 161–5.
25. Rodríguez-Martínezemail J., Ballesta S., Pascual A. Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms // Int. J. Antimicrob. Agents. – 2007; 30: 366–8.
26. Drago L., Mattina R., Legnani D. et al. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone // Int. J. Immunopathol. Pharmacol. – 2011; 24 (4): 1027–35.
27. Bachmann S., Vande-Walle K., Ramage G. et al. In vitro activity of caspofungin against Candida albicans biofilms // Antimicrobiol. Agents Chemother. – 2002; 46: 3591–6.
28. Tang H., Chen C., Cheng K. et al. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms // J. Antimicrob. Chemother. – 2012; 67 (4): 944–50.
29. Apisarnthanarak A., Mundy L. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4th infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin // Int. J. Antimicrob. Agents. – 2012; 39 (3): 271–2.
30. Trapnell B., McColley S., Kissner D. et al. Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection // Am. J. Respir. Crit. Care Med. – 2012; 185 (2): 171–8.
31. Вознесенский Н.А. Биопленки – терапевтическая мишень при хронических инфекциях // Пульмонол. и аллергол.. – 2008; 3: 43.
32. Romanò C., Toscano M., Romanò D. et al. Antibiofilm agents and implant-related infections in orthopaedics: where are we? // J. Chemother. – 2013; 25 (2): 67–80.
33. John G., Donale C. Biofilms: architects of disease. In: Connie R.M., Donald C.L., George M., editors. Textbook of diagnostic microbiology. 3rd ed. Saunders, 2007; p. 884–95.
34. Aparna M., Yadav S. Biofilms: microbes and disease // Braz. J. Infect. Dis. – 2008; 12 (6): 526–30.
35. Smith A., Buchinsky F., Post J. Eradicating chronic ear, nose, and throat infections: a systematically conducted literature review of advances in biofilm treatment // Otolaryngol. Head Neck. Surg. – 2011; 144 (3): 338–47.
36. Noszál B., Visky D., Kraszni M. Population, acid-base, and redox properties of N-acetylcysteine conformers // J. Med. Chem. – 2000; 43: 2176–82.
37. Olofsson A., Hermansson M., Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces // Appl. Env. Microbiol. – 2003; 69: 4814–22.
38. Rubin B. Mucolytics, expectorants, and mucokinetic medications // Respir. Care. – 2007; 52: 859–65.
39. Kelly G. Clinical applications of N-acetylcysteine // Altern. Med. Rev. – 1998; 3 (2): 114–27.
40. Rahman I., MacNee W. Antioxidant pharmacological therapies for COPD // Curr. Opin. Pharmacol. – 2012; 12 (3): 256–65.
41. Hui D., Lee N., Chan P. Adjunctive therapies and immunomodulatory agents in the management of severe influenza // Antiviral. Res. – 2013; 98 (3): 410–6.
42. Riise G., Qvarfordt I., Larsson S. et al. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilusinfluenzae to human oropharyngeal epithelial cells in vitro // Respiration. – 2000; 67: 552–8.
43. Riise G., Larsson S., Andersson B. Bacterial adhesion to oropharyngeal and bronchial epithelial cells in smokers with chronic bronchitis and in healthy nonsmokers // Eur. Respir. J. – 1994; 7 (10): 1759–64.
44. Noszál B., Visky D., Kraszni M. Population, acid-base, and redox properties of N-acetylcysteine conformers // J. Med. Chem. – 2000; 43: 2176–82.
45. Olofsson A., Hermansson M., Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces // Appl. Environ Microbiol. – 2003; 69: 4814–22.
46. Hafez M., Aboulwafa M., Yassien M. et al. Activity of some mucolytics against bacterial adherence to mammalian cells // Appl. Biochem. Biotechnol. – 2009; 158: 97–112.
47. Schwandt L., Weissenbruch R., Stokroos I. et al. Prevention of biofilm formation by dairy products and N-acetylcysteine on voice prostheses in an artificial throat // Acta Otolaryngol. – 2004; 124: 726–31.
48. Huynh H., Couper R., Tran C. et al. N-Acetylcysteine, a novel treatment for Helicobacter pylori Infection // Dig. Dis. Sci. – 2004; 49: 1853–86.
49. Zhao T., Liu Y. N-Acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa // BMC Microbiol. – 2010; 10: 140.
50. Quah S., Wu S., Lui J. et al. N-Acetylcysteine inhibits growth and eradicates biofilm of Enterococcus faecalis // J. Endod. – 2012; 38: 81–5.
51. Pérez-Giraldo C., Rodríguez-Benito A., Morán F. et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis // J. Antimicrob. Chemother. – 1997; 39: 643–6.
52. Mansouri M., Darouiche R. In vitro antimicrobial activity of N-acetylcysteine against bacteria colonising central venous catheters // Int. J. Antimicrob. Agents. – 2007; 29 (4): 474–6.
53. Parry M., Neu H. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro // J. Clin. Microbiol. – 1977; 5 (1): 58–61.
54. Roberts D., Cole P. N-acetylcysteine potentiates the anti-pseudomonas activity of carbenicillin in vitro // J. Infect. – 1981; 3 (4): 353–9.
55. Vecchiarelli A., Dottorini M., Pietrella D. et al. Macrophage activation by N-acetylcysteine in COPD patients // Chest. – 1994; 105: 806–11.
56. Oddera S., Silvestri M., Sacco O. et al. N-acetylcysteine enhances in vitro the intracellular killing of Staphylococcus aureus by human alveolar macrophages and blood polymorphonuclear leukocytes and partially protects phagocytes from self-killing // Lab. Clin. Med. – 1994; 124 (2): 293–301.
57. Marchese A., Bozzolasco M., Gualco L. et al. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms // Int. J. Antimicrob. Agents. – 2003; 22 (2): 95–100.
58. El-Feky M., El-Rehewy M., Hassan M. et al. Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces // Pol. J. Microbiol. – 2009; 58 (3): 261–7.
59. Choe W., Murray M., Stidham K. et al. N-Acetylcysteine as an adjunct for refractory ear infections // Otol. Neurotol. – 2007; 28 (8): 1022–5.
60. Macchi A., Ardito F., Marchese A. et al. Efficacy of N-acetylcisteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upperrespiratory tract infections even if sustained by bacterial biofilms // J. Chemother. – 2006; 18: 507–13.
61. Leite B., Gomes F., Teixeira P. et al. Staphylococcus epidermidis biofilms control by N-acetylcysteine and rifampicin // Am. J. Ther. – 2013; 20 (4): 322–8.
62. Leite B., Gomes F., Teixeira P. et al. Combined effect of linezolid and N-acetylcysteine against Staphylococcus epidermidis biofilms // Enferm. Infect. Microbiol. Clin. – 2013 Apr. 30. (Epub. ahead of print).
63. Aslam S., Trautner B., Ramanathan V. et al. Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia // Infect. Control Hosp. Epidemiol. – 2008; 29 (9): 894–7.
64. Hernandez M., Mansouri M., Aslam S. et al. Efficacy of combination of N-acetylcysteine, gentamicin, and amphotericin B for prevention of microbial colonization of ventricular assist devices // Infect. Control Hosp. Epidemiol. – 2009; 30 (2): 190–2.
65. Tokgoz B., Ucar C., Kocyigit I. et al. Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis // Nephrol. Dial. Transplant. – 2011; 26 (12): 4073–8.
66. Grant L., Rockey D. Drug-induced liver injury // Curr. Opin. Gastroenterol. – 2012; 28 (3): 198–202.
67. Jones A., Helm J. Emerging treatments in cystic fibrosis // Drugs. – 2009; 69 (14): 1903–10.
68. Romanò C., Toscano M., Romanò D. et al. Antibiofilm agents and implant-related infections in orthopaedics: where are we? // J. Chemother. – 2013; 25 (2): 67–80.
69. Abolella H., Abd El-Baky R., Gad G. Effect of oral N-acetyl-cysteine on eradication of Helicobacter pylori in patients with dyspepsia // Min. Gastroenterol. Dietol. – 2013; 59 (1): 107–12.
70. Karbasi A., Hossein-Hosseini S., Shohrati M. et al. Update on triple therapy for eradication of Helicobacter pylori: current status of the art // Clin. Exp. Gastroenterol. – 2012; 5: 151–7.
71. Cammarota G., Sanguinetti M., Gallo A. et al. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection // Aliment. Pharmacol. Ther. – 2012; 36 (3): 222–30.
72. Mansouri M., Hull R., Stager C. et al. In vitro activity and durability of a combination of an antibiofilm and an antibiotic against vascular catheter colonization // Antimicrob. Agents Chemother. – 2013; 57 (1): 621–5.

 

 

 
Рассылка
Важно

→ Фармакопейные статьи


→ Медицинские архивы на службе современного врача


→ Перечень медицинских технологий

ЭКД архив

 

Баннер
Баннер
Баннер
Информационные партнеры:
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер